Ulwazi oluyisisekelo
Igama Lomkhiqizo | Ikhathalogi | Uhlobo | Umsingathi/Umthombo | Ukusetshenziswa | Izinhlelo zokusebenza | I-COA |
I-HCV Core-NS3-NS5 fusion antigen | BMGHCV101 | I-Antigen | I-Ecoli | Thwebula | LF, IFA, IB, WB | Landa |
I-HCV Core-NS3-NS5 fusion antigen | BMGHCV102 | I-Antigen | I-Ecoli | Hlanganisa | LF, IFA, IB, WB | Landa |
Iziguli eziningi azinazo izimpawu ezisobala esigabeni esibucayi sokutheleleka, okuhambisana namazinga aphezulu e-viremia kanye nokuphakama kwe-ALT.I-HCV RNA yavela egazini ngaphambi kwe-anti HCV ngemva kokutheleleka nge-HCV eyingozi.I-HCV RNA ingatholwa emavikini ama-2 ngemuva kokuchayeka kusenesikhathi, i-HCV core antigen ingatholwa ezinsukwini ezi-1 kuye kwezi-2 ngemuva kokuvela kwe-HCV RNA, futhi i-anti HCV ayikwazi ukutholwa kuze kube amasonto ayi-8 kuya kwayi-12, okungukuthi, ngemuva kokutheleleka kwe-HCV, cishe amasonto ayi-8-12, i-HCV RNA kuphela engatholwa i-anti, isikhathi sokutholwa kwe-HCV, kanti ubude be-HCV isikhathi sewindi” sihlobene ne-reagent yokuthola (bona Ithebula 1).I-Anti HCV ayilona i-antibody evikelayo, kodwa isibonakaliso sokutheleleka kwe-HCV.I-15% ~ 40% yeziguli ezine-acute HCV infection zingasusa ukutheleleka phakathi nezinyanga ezingu-6.Enqubweni yokususa ukutheleleka, izinga le-HCV RNA lingase libe liphansi kakhulu ukuthi lingabonwa, futhi i-anti HCV kuphela enhle;Kodwa-ke, u-65% ~ 80% weziguli azikaqedwa izinyanga ezingu-6, okubizwa ngokuthi ukutheleleka kwe-HCV okungapheli.Lapho isifo sokusha kwesibindi kohlobo C esingapheli sesenzeka, i-HCV RNA titer iqala ukuzinza, futhi ukululama okuzenzakalelayo akuvamile.Ngaphandle kokuthi ukwelashwa okuphumelelayo kwe-antiviral kwenziwa, ukuvunyelwa okuzenzakalelayo kwe-HCV RNA akuvamile ukwenzeka.Emisebenzini yomtholampilo, iningi leziguli ezine-hepatitis C ezingamahlalakhona zine-anti HCV (iziguli ezingenamasosha omzimba, njengeziguli ezinegciwane lesandulela ngculazi, abamukeli bokufakelwa isitho esiqinile, iziguli ezine-hypogammaglobulinemia noma iziguli ze-hemodialysis zingase zibe zingenayo i-anti HCV), kanti i-HCV RNA ingase ibe mihle noma ibe yimbi (izinga le-HCV RNA liphansi ngemva kokwelashwa nge-antiviral).